- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03463694
Edinburgh and Lothian Virus Intervention Study in Kids (ELVIS Kids)
Edinburgh and Lothian Virus Intervention Study in Kids (ELVIS Kids): A Randomised Controlled Trial of Hypertonic Saline Nose Drops in Children With Upper Respiratory Tract Infections
Study Overview
Status
Intervention / Treatment
Detailed Description
The study will run over ~30 months. Children are recruited prior to, or within 48 hours of developing URTI symptoms by advertising in areas such as local schools, nurseries, health centres and workplaces as well as social media. For the purposes of this study an URTI is defined as: at least two respiratory symptoms (nasal stuffiness, runny nose, cough, sore throat, or sneezing) OR one respiratory symptoms and at least one systemic symptom (lethargy, muscle pain, headache, pyrexia ≥38°C).
Willing parents/guardians, of children <7 years of age, will be directed by the study advertising to contact the research team at their local research site if they are interested in participating. Children will be randomised to either a Control arm of standard symptomatic care, or an Intervention arm of 3 drops each nostril of HS at least 4 times a day until 24 hours after asymptomatic or maximum of 28 days. All participants will be requested to obtain a mid-turbinate nasal swab prior to first nasal HS drops (repeated daily for 5 days), a daily symptom diary (CARIFS, a valid illness measure in the UK), and an end of illness questionnaire (healthcare use, adverse events, acceptability, infection in household contacts, parental time taken off usual activities). Parent/guardian of the children allocated to the intervention arm will be taught how to prepare the HS. Parent/guardian of children who are asymptomatic at recruitment are requested to inform CCRF when the child develops an URTI (within 48 hours) and follow the instructions already provided to them when given the go-ahead to start the trial. On day 28, parents/guardians will be contacted to determine if their child suffered from wheeze either during the illness or at any point until day 28. Participation in the study will end on day 28.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Sandeep Ramalingham
- Phone Number: 0131 242 6014
- Email: Sandeep.Ramalingam@nhslothian.scot.nhs.uk
Study Contact Backup
- Name: Phillip Rayson
- Phone Number: 0131 651 9928
- Email: elvis.kids@ed.ac.uk
Study Locations
-
-
-
Edinburgh, United Kingdom, EH9 1LF
- Recruiting
- Childrens' Clinical Research Facility
-
Contact:
- Sandeep Ramalingam
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA
- Children between corrected gestational age of ≥40 weeks and <7 years of age
Children without URTI OR ≤48 hours of URTI* starting.
- A URTI being defined as at least two respiratory symptoms (nasal congestion (i.e. stuffy nose), runny nose, cough, sore throat) OR one respiratory symptom + at least one systemic symptom (Low energy/tired, muscle aches/pains, headache, fever ≥38°C).
EXCLUSION CRITERIA
- Children needing immediate medical attention
- Children using saline drops/sprays at the time of randomisation
- Children on immunosuppressive medication, regular oral/inhaled steroids, regular antibiotics (use of antibiotics is allowed as long as the child does not need regular antibiotics)
- Children with a known chronic illness (e.g. cystic fibrosis, cardiac, renal, liver, lung, neurological conditions) apart from wheeze or asthma which are not exclusions if the child is otherwise well and not on regular steroids)
- Children being followed up for developmental delay
- Children receiving the nasal flu vaccine ≤14 days ago
- Children taking part in another interventional trial
- If parents/guardians indicating that they are unable to comply with the study protocol prior to randomisation
- If parents/guardians are unable to understand written or spoken English
- Children randomised to ELVIS KIDS on a previous episode of URTI
- Children with a concurrently participating sibling
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Hypertonic Saline ~2.6% NaCl
3 drops each nostril of Hypertonic Saline (HS) at least 4 times a day until asymptomatic or maximum of 28 days
|
~2.6% NaCl solution prepared from sea salt
|
NO_INTERVENTION: Standard Care
Control arm of standard symptomatic care only
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to the first report that the child is "not unwell".
Time Frame: Maximum of 28days
|
Time until child not unwell
|
Maximum of 28days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Severity of all symptoms
Time Frame: 1-28 days (or until child is well)
|
Recorded by parents from options: No Problem, Minor Problem,Moderate Problem,Major Problem or Unknown/Not Applicable
|
1-28 days (or until child is well)
|
The length of time for individual symptoms to resolve
Time Frame: 1-28 days (or until child is well)
|
Recorded as: No Problem, Minor Problem,Moderate Problem,Major Problem or Unknown/Not Applicable
|
1-28 days (or until child is well)
|
Severity of individual symptoms
Time Frame: 1-28 days (or until child is well)
|
Recorded by parents from options: No Problem, Minor Problem,Moderate Problem,Major Problem or Unknown/Not Applicable
|
1-28 days (or until child is well)
|
Contacting healthcare (NHS 24, OOH, GP) -Number of participants
Time Frame: 1-28 days (or until child is well)
|
Number of participants
|
1-28 days (or until child is well)
|
Contacting healthcare (NHS 24, OOH, GP) -Frequency of contacts
Time Frame: 1-28 days (or until child is well)
|
Number of contacts
|
1-28 days (or until child is well)
|
Participants needing GP appointments- Number of participants
Time Frame: 1-28 days (or until child is well)
|
Number of appointments
|
1-28 days (or until child is well)
|
Participants needing GP appointments- Frequency of contacts
Time Frame: 1-28 days (or until child is well)
|
Number of appointments
|
1-28 days (or until child is well)
|
Number of participants attending hospital and diagnosis - Number of participants
Time Frame: 1-28 days (or until child is well)
|
Number of participants
|
1-28 days (or until child is well)
|
Number of participants attending hospital and diagnosis - Frequency of contacts
Time Frame: 1-28 days (or until child is well)
|
Number of attendances
|
1-28 days (or until child is well)
|
Length of stay in hospital if admitted
Time Frame: 1-28 days (or until child is well)
|
Length in Days
|
1-28 days (or until child is well)
|
Number of participants reporting wheeze during illness and between end of illness to 28 days
Time Frame: Day 28
|
Number reporting wheeze
|
Day 28
|
Number of participants reporting over the counter medication use
Time Frame: 1-28 days (or until child is well)
|
Number of participants
|
1-28 days (or until child is well)
|
Duration of viral shedding
Time Frame: Days 1-5
|
Viral shedding duration in days
|
Days 1-5
|
Reduction in viral shedding
Time Frame: Days 1-5
|
Log conversion of each positive result will be done using the following formula: (40-CT of specimen)/3.3 to estimate change in shedding.
|
Days 1-5
|
Rate of reduction in viral shedding
Time Frame: Days 1-5
|
Rate of viral shedding duration in days
|
Days 1-5
|
Reduction in transmission to household contacts
Time Frame: 1-28 days (or until child is well)
|
Questionnaire - reported number of adults and children catching URTI
|
1-28 days (or until child is well)
|
Number of participants reporting side effects of nasal drops
Time Frame: 1-28 days (or until child is well)
|
Side effects reported
|
1-28 days (or until child is well)
|
Types and severity of side effects reported
Time Frame: 1-28 days (or until child is well)
|
Side effects reported
|
1-28 days (or until child is well)
|
Number of days lost from school/nursery for child
Time Frame: 1-28 days (or until child is well)
|
Number of days
|
1-28 days (or until child is well)
|
Number of days lost from work for parent/guardian
Time Frame: 1-28 days (or until child is well)
|
Number of days
|
1-28 days (or until child is well)
|
Cost of over the counter medication used
Time Frame: 1-28 days (or until child is well)
|
Cost of medicine used.
|
1-28 days (or until child is well)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sandeep Ramalingham, NHS Lothian
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ELVIS Kids
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pediatric ALL
-
University of BirminghamCompletedCancer | Pediatric ALL | Pediatric Solid Tumor | Pediatric AMLUnited Kingdom, Australia, Netherlands
-
Samsung Medical CenterMinistry of Health, Republic of KoreaRecruitingRelapsed Pediatric AML | Refractory Pediatric AML | Relapsed Pediatric Solid Tumor | Refractory Pediatric Solid TumorKorea, Republic of
-
National Institute of Allergy and Infectious Diseases...Clinical Trials in Organ Transplantation in ChildrenCompletedPediatric Heart Transplantation | Pediatric Heart Transplant Recipients | Pediatric Cardiac TransplantationUnited States
-
University Hospital, Strasbourg, FranceTerminatedPediatric Lung Ultrasound | Pediatric Chest Radiography | Pediatric Lung DiagnosisFrance
-
TC Erciyes UniversityCompletedPediatric Cancer | Pediatric Brain Tumor | Pediatric Solid TumorTurkey
-
National Institute of Allergy and Infectious Diseases...National Heart, Lung, and Blood Institute (NHLBI)TerminatedPediatric Heart Transplantation | Pediatric Heart Transplant RecipientsUnited States, Canada
-
University of CalgaryCanadian Institutes of Health Research (CIHR); Alberta Children's Hospital; Stollery... and other collaboratorsNot yet recruitingPediatric Cancer | Pediatric Hematology
-
Hospital Moinhos de VentoNot yet recruitingAdolescent | Telemedicine | Critical Care | Pediatric | Intensive Care Units, Pediatric
-
Samsung Medical CenterMinistry of Health, Republic of KoreaNot yet recruitingRelapsed Pediatric Solid Tumor | Refractory Pediatric Solid TumorKorea, Republic of
-
Children's Healthcare of AtlantaEmory UniversityCompletedPediatric Preoperative Anxiety, Pediatric CopingUnited States
Clinical Trials on Na Cl solution
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Eye-yon MedicalCompletedCorneal EdemaIsrael
-
Boehringer IngelheimCompleted
-
Nantes University HospitalTerminatedBone Demineralization Lesions in the Injured MarrowFrance
-
PX'TherapeuticsEuropean CommissionCompleted
-
Johns Hopkins UniversityCompletedAlcoholism | Alcohol Related DisordersUnited States